Hybrid Capture assay

Hybrid Capture assay

Lab medicine A proprietary system used to detect and monitor viral–eg, Chlamydia spp, CMV, HBV, HPV infections. See HBV.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
Based on test type, global cytomegalovirus assay market is segmented as below: Serology Cell culture Antigenemia Polymerase Chain Reaction Amplification Immunohistochemistry Nucleic acid sequence-based amplification (NASBA) Hybrid capture assay Based on application type, global cytomegalovirus assay market is segmented as below: Retinitis Pneumonia Gastrointestinal Ulcers Encephalitis Others (Mouth Ulcers, Pharyngitis, etc.) Based on end user, global cytomegalovirus assay market is segmented as below: Hospitals Diagnostic Centers Others Cytomegalovirus Assay Market : Overview Increase in cytomegalovirus infection cases propel the growth of the assay market.
These methods perform as well as Hybrid Capture assay, however, with the added benefit of being able to discriminate which HPV subtype is present.
The Hybrid Capture assay (hc2) is a batch test based on hybridization in a solution of long synthetic RNA probes.
Detection of Human Papillomavirus DNA by the Hybrid Capture Assay. Braz J Infect Dis 2003;7(2):121-5.
Use of a hybrid capture assay of self-collected swabs in rural Uganda for detection of human papilloma virus.
Two such assays are the hybrid capture assay (Digene Corp.) and Amplicor CMV Monitor Test (Roche Molecular Systems).
Furthermore, evaluations of women with higher median age often detect HPV DNA in only 30% to 60% of women with low-grade cervical intraepithelial neoplasia (CIN).[12-14] In contrast, Chesebro and colleagues,[15] reporting on a young population of women, detected high-risk HPV by Hybrid Capture assay (Digene Diagnostics, Silver Spring, Md) in 80% referred with an LSIL Pap smear report, indicating that misclassification of LSIL at this age is rare.
In the present study, we associated the cytological diagnosis with the hybrid capture assay. We observed HPV DNA in 488 cases of the 1120 smears (43.5%) diagnosed as a LSIL and 632 (56.4%) were negative.
An example of this is the Hybrid Capture assay (Digene Corp.), which uses antibodies that bind to RNA:DNA hybrids to detect hybrid formation.
The Hybrid Capture Assay I (HC-I) was first introduced by Digene in 1995.
(Toronto), the HPV-DNA test uses the Digene hybrid capture assay to detect the presence of high-risk human papillomavirus infection, which is present in 99% of cervical cancer cases.